Skip to Content

Publications Search - Abstract View

Title: Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.
Authors: Clarke MA,  Wentzensen N,  Mirabello L,  Ghosh A,  Wacholder S,  Harari A,  Lorincz A,  Schiffman M,  Burk RD
Journal: Cancer Epidemiol Biomarkers Prev
Date: 2012 Dec
Branches: BB, CGB, HREB
PubMed ID: 23035178
PMC ID: PMC3664203
Abstract: Sexually transmitted carcinogenic human papillomavirus (HPV) infections are extraordinarily prevalent worldwide. However, most incident HPV infections clear within a few years, whereas a small minority persists to invasive cancer. Recent studies indicate that detection of methylated viral DNA may distinguish women with cervical intraepithelial neoplasia grade 2+ (CIN2+) from those with a carcinogenic HPV-type infection that shows no evidence of CIN2+. Several studies have reported a positive association between methylation of CpG sites in the L1 gene and CIN2+, although there are inconclusive results about methylation of CpG sites in the upstream regulatory region (URR). In this review, we summarize the current state of knowledge on HPV DNA methylation in cervical carcinogenesis, and discuss the merits of different methods used to measure HPV DNA methylation. To follow the promising leads, we suggest future studies to validate the use of methylated carcinogenic HPV DNA as a predictive and/or diagnostic biomarker for risk of cervical cancer among HPV-positive women.